Mp68-13 Trends and Predictors of Mri-Guided Biopsy for Prostate Cancer Diagnosis in the United States

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II (MP68)1 May 2024MP68-13 TRENDS AND PREDICTORS OF MRI-GUIDED BIOPSY FOR PROSTATE CANCER DIAGNOSIS IN THE UNITED STATES Mollie Goldman, Camilo Arenas-Gallo, Adithya Balasubramanian, Jack Millot, Leo D. Dreyfuss, Patrick Lewicki, Xian Wu, Stephen Rhodes, and Jonathan E. Shoag Mollie GoldmanMollie Goldman , Camilo Arenas-GalloCamilo Arenas-Gallo , Adithya BalasubramanianAdithya Balasubramanian , Jack MillotJack Millot , Leo D. DreyfussLeo D. Dreyfuss , Patrick LewickiPatrick Lewicki , Xian WuXian Wu , Stephen RhodesStephen Rhodes , and Jonathan E. ShoagJonathan E. Shoag View All Author Informationhttps://doi.org/10.1097/01.JU.0001008744.60568.e8.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Multiparametric magnetic resonance imaging (MRI) before prostate biopsy enhances the detection of clinically significant prostate cancer (PCa) over traditional transrectal ultrasound guided biopsy and is recommended by guidelines. We evaluated adoption trends and predictors of MRI-guided prostate biopsy (MRI-Bx) in the United States. METHODS: A retrospective study was conducted using the Marketscan Database (Commercial and Medicare Claims) to identify men with a prostate MRI claim within 9 months before a prostate biopsy from 2012 to 2021. CPT and ICD9/10 codes determined MRI-Bx cases. Men with prior PCa diagnosis, treatment, or metastasis before biopsy were excluded. We analyzed the proportion of MRI-Bx by plan type and prior biopsy status. Multivariable logistic regression was used to identify predictors of MRI-Bx use. RESULTS: The final cohort included 256,961 men, with a mean age of 61.7±8 years (Table 1). By 2021, MRI-Bx accounted for 27.04% of biopsy-naive commercially insured patients and 61.85% of those had a previous biopsy. Among Medicare insured, 27.14% of biopsy-naive patients and 51.89% of those with prior biopsies underwent MRI-Bx (Figure 1). A 20-fold increase in MRI-Bx use was observed throughout the study period. Men with a previous biopsy were 6 times more likely to receive MRI-Bx (Odd Ration (OR): 6.07, 95% CI: 5.25-7.03, p<0.001). Living in a metropolitan statistical area also increased the odds of having MRI-Bx (OR: 1.95, CI: 1.67-2.28, p<0.001). There were no significant differences in MRI-Bx use when comparing Medicare to commercially insured (OR: 1.08, 95% CI: 0.99-1.17, p=0.086), or high versus low deductible plans (OR: 0.99, 95% CI: 0.86-1.14, p=0.093). CONCLUSIONS: MRI use prior to prostate biopsy has significantly increased in recent years. Predictive factors for MRI-Bx include a previous biopsy and residing in a metropolitan area, with no significant differences observed between insurance types or deductible levels. Download PPT Source of Funding: The work presented here was not directly funded by an outside organization or sponsor. JES is supported by the Frederick J. and Theresa Dow Fund of the New York Community Trust, the Vinney Scholars Award, and a Damon Runyon Cancer Research Foundation Physician Scientist Training Award © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1113 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Mollie Goldman More articles by this author Camilo Arenas-Gallo More articles by this author Adithya Balasubramanian More articles by this author Jack Millot More articles by this author Leo D. Dreyfuss More articles by this author Patrick Lewicki More articles by this author Xian Wu More articles by this author Stephen Rhodes More articles by this author Jonathan E. Shoag More articles by this author Expand All Advertisement PDF downloadLoading ...